Betrixaban
>98%
- Product Code: 103547
CAS:
330942-05-7
| Molecular Weight: | 451.91 g./mol | Molecular Formula: | C₂₃H₂₂ClN₅O₃ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Betrixaban is primarily used as an anticoagulant to prevent blood clots in patients who are at risk due to certain medical conditions. It is often prescribed for adults hospitalized with acute medical illnesses, such as heart failure, severe respiratory issues, or infections, to reduce the risk of venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE).
This medication works by inhibiting Factor Xa, a key component in the blood clotting process, thereby preventing the formation of clots. It is particularly beneficial for patients who cannot take other anticoagulants due to contraindications or side effects. Betrixaban is administered orally, making it a convenient option for extended use in both hospital and outpatient settings.
Its application is especially important for patients with limited mobility or those recovering from surgery, as they are at a higher risk of developing blood clots. By reducing this risk, Betrixaban helps improve patient outcomes and supports recovery during critical periods of immobility or illness.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | Off-White Solid |
| Purity (%) | 97.5-100 |
| Infrared Spectrum | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.010 | 10-20 days | ฿5,751.00 |
+
-
|
| 0.050 | 10-20 days | ฿14,391.00 |
+
-
|
| 0.100 | 10-20 days | ฿22,248.00 |
+
-
|
Betrixaban
Betrixaban is primarily used as an anticoagulant to prevent blood clots in patients who are at risk due to certain medical conditions. It is often prescribed for adults hospitalized with acute medical illnesses, such as heart failure, severe respiratory issues, or infections, to reduce the risk of venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE).
This medication works by inhibiting Factor Xa, a key component in the blood clotting process, thereby preventing the formation of clots. It is particularly beneficial for patients who cannot take other anticoagulants due to contraindications or side effects. Betrixaban is administered orally, making it a convenient option for extended use in both hospital and outpatient settings.
Its application is especially important for patients with limited mobility or those recovering from surgery, as they are at a higher risk of developing blood clots. By reducing this risk, Betrixaban helps improve patient outcomes and supports recovery during critical periods of immobility or illness.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :